Randomized Open-Label Phase II Study of Decitabine in Patients With Low- or Intermediate-Risk Myelodysplastic Syndromes

PURPOSE: This open-label, randomized phase II trial assessed efficacy and tolerability of two low-dose regimens of subcutaneous (SC) decitabine in patients with low- or intermediate-1–risk myelodysplastic syndrome (MDS). PATIENTS AND METHODS: Patients received decitabine 20 mg/m(2) SC per day for 3...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Clin Oncol
Päätekijät: Garcia-Manero, Guillermo, Jabbour, Elias, Borthakur, Gautam, Faderl, Stefan, Estrov, Zeev, Yang, Hui, Maddipoti, Sirisha, Godley, Lucy A., Gabrail, Nashat, Berdeja, Jesus G., Nadeem, Ahmed, Kassalow, Laurent, Kantarjian, Hagop
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Clinical Oncology 2013
Aiheet:
ORIGINAL REPORTS
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4878053/
https://ncbi.nlm.nih.gov/pubmed/23733767
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.44.6823
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia